Compare AbCellera Biologics Inc (ABCL) vs Modine Manufacturing Company (MOD) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbCellera Biologics Inc vs Modine Manufacturing Company — how do they compare? AbCellera Biologics Inc trades at $7.18 (market cap $2.35B), while Modine Manufacturing Company trades at $226.59 (market cap $12.17B). The key difference: Modine Manufacturing Company is far larger — about 5.2× AbCellera Biologics Inc's market cap, and AbCellera Biologics Inc is trading nearer its 52-week high, Modine Manufacturing Company nearer its low. Which is the better fit depends on your goals.
| ABCL | MOD | |
|---|---|---|
Market Cap | $2.35B | $12.17B |
Sector | Health | Technology |
52-Week High | $8.12 | $306.89 |
52-Week Low | $2.78 | $90.02 |
Enterprise Value | $1.99B | $12.53B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbCellera Biologics (ABCL) trades at $7.69, down 5.18% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of -$146.41M in 2025, with negative margins, though revenue grew to $75.13M. Recent news highlights a major collaboration with Jazz Pharmaceuticals worth up to $876M, potentially boosting future revenue streams. Analyst consensus is strongly bullish with a $9.67 price target, indicating 25.7% upside.
The outlook hinges on execution of new partnerships and pipeline progress, particularly ABCL635 Phase 2 data expected in Q3 2026. Key risks include persistent cash burn, high valuation multiples despite losses, and biotech sector volatility. Investors should weigh the strong analyst support against fundamental challenges and the stock's current technical overbought condition.
Modine (MOD) trades at $235.19, up 1.83% on the day, amid a bearish technical signal despite recent earnings beats. The company reported strong revenue growth to $2.58B in 2025, with net income of $184M, though 2026 projections show margin compression. Analyst consensus remains strongly bullish with a $328.80 price target, driven by optimism around its data center cooling business, which is expected to grow 60-80% in FY27 according to Seeking Alpha (2026-06-11).
The outlook is mixed: robust growth in data center demand offers significant upside, but high valuations (P/E 104.07) and near-term technical weakness pose risks. Investors face volatility from supply chain challenges and competitive pressures in the HVAC segment, though institutional support and consistent earnings outperformance provide a foundation for long-term growth if execution continues.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.
Read more on ABCL →About Modine Manufacturing Company
Modine Manufacturing Company is a global leader in thermal management technology and solutions. The company engineers, manufactures, and markets heat transfer products for a wide range of applications across the automotive, commercial, industrial, and HVAC (heating, ventilation, and air conditioning) markets. Modine's products include engine cooling systems, heat exchangers, and ventilation systems, providing critical thermal solutions for vehicles, data centers, and various equipment worldwide.
Read more on MOD →
